Corcept Therapeutics (NASDAQ:CORT) Receives Buy Rating from HC Wainwright

Corcept Therapeutics (NASDAQ:CORT)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research note issued to investors on Thursday,Benzinga reports. They presently have a $115.00 price objective on the biotechnology company’s stock. HC Wainwright’s price objective suggests a potential upside of 89.83% from the stock’s current price. HC Wainwright also issued estimates for Corcept Therapeutics’ Q4 2025 earnings at $0.73 EPS and FY2029 earnings at $8.52 EPS.

Other equities research analysts also recently issued reports about the stock. StockNews.com downgraded shares of Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 25th. Canaccord Genuity Group lifted their price objective on shares of Corcept Therapeutics from $78.00 to $130.00 and gave the stock a “buy” rating in a research note on Thursday, January 30th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $99.75.

Corcept Therapeutics Trading Up 1.2 %

NASDAQ:CORT opened at $60.58 on Thursday. Corcept Therapeutics has a 12 month low of $20.84 and a 12 month high of $75.00. The firm has a fifty day simple moving average of $59.78 and a 200-day simple moving average of $51.22. The company has a current ratio of 3.70, a quick ratio of 3.64 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $6.35 billion, a P/E ratio of 48.08 and a beta of 0.58.

Corcept Therapeutics (NASDAQ:CORT) last posted its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $0.26 EPS for the quarter, missing the consensus estimate of $0.37 by ($0.11). Corcept Therapeutics had a return on equity of 24.54% and a net margin of 22.35%. The company had revenue of $181.89 million for the quarter, compared to analyst estimates of $200.12 million. On average, equities research analysts anticipate that Corcept Therapeutics will post 1.36 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Daniel N. Swisher, Jr. sold 2,200 shares of the firm’s stock in a transaction on Friday, January 10th. The shares were sold at an average price of $50.54, for a total transaction of $111,188.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Sean Maduck sold 20,000 shares of the firm’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $50.39, for a total transaction of $1,007,800.00. Following the transaction, the insider now directly owns 85,318 shares of the company’s stock, valued at approximately $4,299,174.02. This trade represents a 18.99 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 26,600 shares of company stock valued at $1,399,576 over the last 90 days. Insiders own 20.50% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CORT. Capital Performance Advisors LLP purchased a new position in Corcept Therapeutics in the third quarter valued at $25,000. Kestra Investment Management LLC purchased a new position in Corcept Therapeutics in the fourth quarter valued at $27,000. Canada Pension Plan Investment Board purchased a new position in Corcept Therapeutics in the fourth quarter valued at $40,000. National Bank of Canada FI purchased a new position in Corcept Therapeutics in the fourth quarter valued at $42,000. Finally, USA Financial Formulas purchased a new position in Corcept Therapeutics in the fourth quarter valued at $54,000. Hedge funds and other institutional investors own 93.61% of the company’s stock.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.